Welcome to Medpharm Publications

Medpharm Publications was founded in 1988 and has established itself as the largest medical and pharmaceutical journal publisher in South Africa.

With a publications list of more than ten titles comprising of over fifty journal editions, Medpharm Publications reach more than 40 000 healthcare workers countrywide with printed editions, and has established a global audience with the online editions.

The majority of Medpharm Publications’ journals are associated with professional or scholarly societies and acts as the official South African mouthpiece in the associated discipline. All journals are web-based, most of which are fully peer-reviewed, with five titles accredited by the South African Department of Higher Education and Training (DHET) to earn research subsidies for academic departments.

As a publisher, passionate about journal publishing, we believe that South African researchers and clinicians can and will make a significant contribution to world medical literature.

South Africa’s vaccination drive needs renewed urgency

This African Vaccination Week Sanofi South Africa reaffirms its commitment to vaccine awareness, access and public health partnerships to close the immunisation gap

SA medtech company AI Diagnostics raises R85 million to accelerate AI-powered TB screening

A South African medtech company has secured R85 million in funding to advance the use of its proprietary hardware and AI software in combatting the tuberculosis (TB) epidemic. The affordable solution, praised by investors for its social impact and innovation, makes TB screening easy and accessible for frontline health workers.

One Africa, one cure: Making CAR-T Cell therapy accessible across Africa

CAR-T cell therapy is a form of personalised medicine in which a person’s own immune cells are collected and modified in a specialised laboratory so they can better recognise and attack certain blood cancers. It is used in some countries for patients with specific types of lymphoma and leukaemia when other treatments have not worked. It is only available in a few highly specialised hospitals around the world.

Rare Disease Day 2026 puts equity for patients in the spotlight

Rare diseases each affect relatively small numbers of people, but collectively they impact more than 300 million individuals worldwide across over 7,000 known conditions, with 70% of these starting in childhood.1 For many patients and families, the reality is often long diagnostic journeys, uncertainty and ongoing challenges in accessing treatment and support.

Sanofi receives registration for Beyfortus® in South Africa to protect infants against RSV

Sanofi is pleased to share that the South African Health Products Regulatory Authority (SAHPRA) has granted registration for Beyfortus® (nirsevimab), a long-acting monoclonal antibody designed to protect infants against Respiratory Syncytial Virus (RSV).